ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,473.14
0.23%
US Tech 100
19,195.60
0.16%
다우존스 지수
39,310.46
0.49%
Bitcoin
62,732.56
0.20%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) 뉴스

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CGEM
일자시간출처헤드라인심볼기업
2024/06/0513:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0506:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0321:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0120:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/2421:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/2406:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/2406:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
2024/05/1705:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
2024/05/1620:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/1619:42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/1619:40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/1605:05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/0908:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/0705:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/04/2920:00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
2024/04/2423:09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
2024/04/1620:00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
2024/04/1619:59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
2024/03/1420:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
2024/03/0121:00GlobeNewswire Inc.Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/2722:00GlobeNewswire Inc.Cullinan Oncology to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/2407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/2407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/2407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/1511:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/0311:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/02/0206:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/01/3109:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/01/3006:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/01/2507:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
 검색 관련기사 보기:NASDAQ:CGEM

최근 히스토리

FX
USDEUR
US Dollar vs Euro
COIN
SOLUSD
Solana
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
NYSE
VZ
Verizon Communications
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
NYSE
CVX
Chevron
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
CCOM
US500
US 500
FX
USDJPY
US Dollar vs Yen
AMEX
XLV
Health Care Select Sector
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유